# EDGAR Filing Document

**Accession Number:** 0001873093
**File Stem:** 0001493152-23-009686
**Filing Date:** 2023-3
**Character Count:** 4467
**Document Hash:** ef25bf78e1b0c58dbdf2b75b42548866
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-009686.hdr.sgml**: 20230330

**ACCESSION NUMBER**: 0001493152-23-009686

**CONFORMED SUBMISSION TYPE**: 8-A12B

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230330

**DATE AS OF CHANGE**: 20230330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CytoMed Therapeutics Ltd
- **CENTRAL INDEX KEY:** 0001873093
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** U0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-A12B
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41677
- **FILM NUMBER:** 23779835

**BUSINESS ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544
- **BUSINESS PHONE:** 603824911

**MAIL ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CytoMed Therapeutics Pte. Ltd.
- **DATE OF NAME CHANGE:** 20210716

**U.S. SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES**

**PURSUANT TO SECTION 12(b) OR 12(g) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**CytoMed Therapeutics Limited**

(Exact Name of Registrant as Specified in Its Charter)

---

| | |
|:---|:---|
| **Singapore** | **Not Applicable** |
| (State of Incorporation or Organization) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **1 Commonwealth Lane #08-22**<br> **Singapore**  | **149544** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Securities to be registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| Title of Each Class<br> to be Registered | Name of Each Exchange on Which<br> Each Class is to be Registered |
| **Ordinary shares, no par value** | **The Nasdaq Stock Market LLC** |

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), please check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), please check the following box. ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

---

| | |
|:---|:---|
| Securities Act registration statement or Regulation A offering statement file number to which this form relates: | **333-268456** |
|  | (If applicable) |

---

**Securities to be registered pursuant to Section 12(g) of the Act:**

**N/A**

(Title of Class)

**Item 1. Description of Registrant's Securities to be Registered.**

The securities to be registered hereby are the shares of ordinary shares, no par value (the "**Ordinary shares**"), of CytoMed Therapeutics Limited (the "**Company**"). The description of Ordinary shares contained in the section entitled "Description of Share Capital" in the prospectus included in the Company's Registration Statement on Form F-1 (File No. 333-268456) originally filed with the Securities and Exchange Commission on November 18, 2022, as amended from time to time (the "**Registration Statement**"), to which this Form 8-A relates, is incorporated herein by reference. Any form of prospectus or prospectus supplement to the Registration Statement that includes such descriptions and that is subsequently filed is also incorporated by reference herein.

**Item 2. Exhibits.**

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed, because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | |
|:---|:---|
| **CYTOMED THERAPEUTICS LIMITED** | **CYTOMED THERAPEUTICS LIMITED** |
| By: | */s/ CHOO Chee Kong* |
|  | CHOO Chee Kong |
|  | Chairman and Director |

---

Dated: March 30, 2023